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Abstract 
Neurotrophic factors (NTFs) promote nerve regeneration and neuronal survival after 
peripheral nerve injury. However, drawbacks related with administration and bioactivity 
during long periods limit their therapeutic application. In this study, PLGA microspheres 
(MPs) were used to locally release different NTFs and evaluate whether they 
accelerate axonal regeneration in comparison with free NTFs or controls. ELISA, SEM, 
UV/visible light microscopy, organotypic cultures of DRG explants and spinal cord 
slices were used to characterize MP properties and the bioactivity of the released 
NTFs. Results of organotypic cultures showed that encapsulated NTFs maintain longer 
bioactivity and enhance neurite regeneration of both sensory and motor neurons 
compared with free NTFs. For in vivo assays, the rat sciatic nerve was transected and 
repaired with a silicone tube filled with collagen gel or collagen mixed with PBS 
encapsulated MPs (control groups) and with free or encapsulated NGF, BDNF, GDNF 
or FGF-2. After 20 days, a retrotracer was applied to the regenerated nerve to quantify 
motor and sensory axonal regeneration. NTF encapsulation in MPs improved 
regeneration of both motor and sensory axons, as evidenced by increased numbers of 
retrolabeled neurons. Hence, our results show that slow release of NTFs with PLGA 
MP enhance nerve regeneration. 
 
 
 
Keywords: growth factors, microspheres, motor axons, nerve conduit, nerve 
regeneration, sensory axons.  
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1. Introduction 
Peripheral neurons are able to regenerate their axons after nerve injuries and 
reinnervate end organs, although functional recovery is often poor. After nerve 
transection, surgical repair is mandatory to rejoin the nerve stumps allowing axons to 
find an adequate substrate to grow distally. Direct suture of the two stumps or 
interposition of an autologous graft when the interstump defect is long are considered 
the standard option for repairing a nerve transection. The use of nerve conduits to 
bridge short or mid length gaps is a good alternative to autografts (Arslantunali et al., 
2014), although regeneration is slowed during the initial phase compared to autograft 
(Boeckstyns et al., 2013). Several parameters affect the rate of axonal regeneration, 
including the distance between stumps (Scherman et al., 2001), the age of the subject 
(Kang et al., 2013; Painter et al., 2014; Verdú et al., 2008), the time after repair and the 
distance between the lesion site and end organ (Gordon et al., 2003). Indeed, the time 
from injury to target reinnervation is the most important predictor of the degree of 
functional recovery (Krarup et al., 2002), emphasizing that factors that control early 
axonal outgrowth influence the final level of recovery attained even years later. 
Therefore, strategies to accelerate the rate of axonal growth could be useful to 
stimulate nerve regeneration through longer distances and improve the recovery 
outcome. In fact, different strategies have already been developed to solve this 
problem including the use of different neurotrophic factors (NTFs) (Allodi et al., 2012). 
After nerve injury, NTFs are synthesized and secreted not only at the spinal 
cord (SC) and the dorsal root ganglia (DRG) where the somas of the injured neurons 
are located, but mainly at the site of the lesion by reactive Schwann cells. NTFs have 
been long studied for their positive effects on nerve regeneration, including their ability 
to promote neuronal survival, to increase axonal outgrowth and to improve target 
reinnervation. Different NTFs have been tested in vitro and in vivo to improve 
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peripheral nerve regeneration, such as nerve growth factor (NGF) (Kemp et al., 2011; 
Lee et al., 2003), brain-derived neurotrophic factor (BDNF) (Vögelin et al., 2006), 
neurotrophin-3 (NT-3) (Sternel et al., 1997), glial cell-derived neurotrophic factor 
(GDNF) (Moore et al., 2010), fibroblast growth factors (FGF1, FGF2)  (Midha et al., 
2003; Allodi et al., 2013) or insulin like growth factors (IGF1, IGF2)  (Ishi et al., 1993; 
Kanje et al., 1989). 
The induction of an increased production of NTFs at the site of the lesion will 
stimulate axonal regeneration when the local environment is poor. Thus, the 
combination of a nerve conduit with NTFs appears as a good option to enhance nerve 
regeneration. However, NTFs added within a nerve conduit can be rapidly degraded 
(Ejstrup et al., 2010; Tria et al., 1994), diffuse outside the conduit or get diluted after 
liquid infiltration resulting in sub-optimal concentrations, and thus poor regeneration 
outcome (de Boer et al., 2012; Wood et al., 2013). Hence, a better way to apply NTFs 
and prolong their presence in close contact with regenerating axons and Schwann cells 
is still needed to optimize the effects of NTFs on regeneration. In attempts to increase 
the NTF availability at the site of injury over time, different approaches have been 
utilized by using repeated injections through catheters (Mcdonald et al., 2003), osmotic 
minipumps (Hontanilla et al., 2007), binding to extracellular matrix molecules (Sternel 
et al., 1997; Sakiyama-Elbert et al., 2000; Lee et al., 2003) or to the wall of nerve 
conduits (Madduri et al., 2010; Piquilloud et al., 2007) and gene therapy (Allodi et al., 
2014; Eggers et al., 2013; Haastert et al., 2006). However, these strategies still present 
some difficulties to reach optimal nerve regeneration. 
In this context, strategies involving biocompatible and biodegradable 
microspheres (MPs) associated to selected bioactive molecules may provide a 
sustained and controlled release of factors, offering valuable approaches for 
overcoming those limitations. Nanotechnology-based carrier technologies offer indeed 
a customizable approach for locally controlled delivery, by coupling the drug or 
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molecule of interest to carrier particles such as MPs (Tam et al., 2014), nanoparticles, 
liposomes or dendrimers (Mura et al., 2013). Thanks to relatively simple fabrication 
protocols and fair requests in terms of equipment, such technologies have been 
extensively explored in the last decade, and applied in different fields, spanning from 
cancer research to nutritional sciences (Mozafari et al., 2008; Peer et al., 2007). The 
characteristics of carrier technologies have been developed to overcome hindrances 
arisen in the field of drug administration, thus to improve the selectivity of targeting, to 
increase the capability to control drug release via chemistry tailoring, and to obtain an 
increase of stability of otherwise labile payloads. Despite the myriad different 
chemistries and payloads, the recurring goal has been definitely to exert an otherwise 
difficult control of drug release and stability at the local level. Among polymer-based 
microsphere carrier systems that take advantage of the biocompatible character of bio-
derived substances, such alginate, chitosan and silk fibroin, PLGA (Poly-lactic Co-
Glycolic acid, a synthetic biodegradable polymer) based MPs (Makadia et al., 2011) 
are particularly attractive for neural regeneration applications, given their favorable 
biocompatible behavior in physiological environments, low immunogenicity and toxicity, 
the possibility of size control and predictable, highly tailorable degradation kinetics, not 
mentioning the fact that they are FDA approved for drug delivery use (Jain et al., 2000).  
Finally, the chaotic reinnervation of distal targets due to misdirection of 
regenerating axons is the main factor that results in poor functional recovery after 
nerve transection and tube repair (Valero-Cabré & Navarro, 2002), thus study of 
strategies to improve motor and/or sensory specific reinnervation are still needed. 
Therefore, the objective of the present study was the initial evaluation of the potential 
advantages of sustained release from MPs versus acute supply of several neurotrophic 
factors and their possible selective effects on the regeneration of motor and sensory 
axons.  
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2. Results 
 
2.1. MPs fabrication and characterization 
To test the correct encapsulation of molecules during the MP fabrication 
process, fluorescent FITC-BSA was used as tracking dye and its fluorescence in the 
MP was checked by fluorescence microscopy (Fig. 3). These fluorescent MPs were 
also used as negative control to initially test their biocompatibility in the organotypic 
explant experiments (see 3.2). 
SEM imaging of MPs showed a fairly rough surface (Fig. 1C) and was used also 
as a tool for rapid assessment of particle dispersion, allowing quick modifications of the 
synthesis protocol to obtain narrowly distributed microsphere size by protocol 
adjustment. A consistent change was observed using non-hydrolyzed PVA instead of 
hydrolyzed PVA as dispersant of the second emulsification stage in the fabrication 
protocol. Non-hydrolyzed PVA has higher viscosity and reasonably hampers 
coalescing of the microdroplets formed during the first homogenization phase, thus 
permitting smaller and narrowly distributed MP sizes. 
To assess the mean MP size, as Dynamic Light Scattering (DLS) was not 
feasible due the micrometric size of the particles, an optical microscopy-based method 
was implemented as described. Figure 1 shows the sequential steps of the software 
pipeline, from the starting image taken in visible light (Fig. 1A), proceeding through 
normalization, thresholding binarization, particle recognition and counting (Fig. 1B), 
with final summarization of statistical distribution of the measured diameters 
(expressed as Feret’s diameter) of the MP (Fig. 1D). The particles produced by this 
protocol have a narrow size distribution with a mean size of 5.9±2.1 µm (n=6823). This 
is a desirable size range, as nanometer-sized MPs would likely be endocythosed by 
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cells, while bigger ones would be difficult to handle due to quick precipitation after 
resuspension.  
The encapsulation efficiency was calculated as the actual fraction of a 
theoretical 100% efficiency. By ELISA tests the estimated encapsulation efficiency 
resulted to be 64.1±0.02%, that, while being lower than otherwise reachable high 
reported efficiencies (Péan et al., 1998), also in view of smaller mean particle size, 
compares with previous work with similar applications (de Boer et al., 2011). This 
estimate was used to calculate the mass of MP to use when assessing the release 
profile of NGF. Quantification of the released NGF was performed by ELISA, starting 
with an estimated 50 ng NGF-containing MP mass (equivalent to 62.5 µg) and 
measuring the NGF quantity in the supernatant of a suspension of MPs kept in cell 
culture-like conditions (37°C, 5% CO2 atmosphere) over one month. The resulting data 
(shown in Fig. 2 as percentage quantity of the total initial estimated NGF) showed an 
initial small burst at day 0 (sampling was performed at the end of each considered day) 
and increasing release over the first 8-10 days of suspension, followed by sustained 
release until the end of the observation period.   
 
2.2. In vitro effects of NTF loaded MP on neurite outgrowth 
Although PLGA has been widely described to be biocompatible and 
biodegradable (Makadia et al., 2011), there are studies reporting some cell toxicity in 
culture (Grabowski et al., 2013). Thus, we first evaluated if PLGA MPs could affect 
neurite outgrowth by loading FITC-BSA in the MPs and embedding them within the 
collagen matrix surrounding DRG and SC cultures. In both cases neurites grew from 
the explants and were present in close proximity to the MPs (Fig. 3A, B), indicating no 
adverse effects caused by PLGA or PLGA degradation products that could interact with 
neurite outgrowth.  
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Organotypic cultures of DRG (Fig. 4A-F) and SC (Fig. 5A-F) were performed to 
test whether MPs loaded with NGF (MP-NGF) and with BDNF (MP-BDNF) increased 
neurite outgrowth in comparison with the same NTF placed as free protein in the 
collagen matrix. Without conditioning the collagen matrix, both free and encapsulated 
NTF increased the amount of neurites that grew from the explant in comparison with 
cultures without NTF (Fig. 4G and 5G), indicating that MPs released NTF. The longest 
neurite measured was significantly longer in DRG cultures with free NGF but not in 
cultures with MP-NGF than in control cultures (Fig. 4H). In SC cultures both free BDNF 
and MP-BDNF increased the maximal length of neurites with respect to control cultures 
(Fig. 5H).  
After 1 week of conditioning the collagen matrix with no NTF, free NTF or 
encapsulated NTF, only the explants cultured with MPs increased the amount of 
neurites in comparison with the control and also free NTF (Fig. 4I and 5I), indicating 
that after 1 week there was still NTF within the matrix of the MP conditions being able 
to promote axon outgrowth but not in the free NTF cultures. Similarly, both MP-NGF 
(Fig. 4J) and MP-BDNF (Fig. 5J) cultures showed increase in the longest neurite 
measures with respect to control values, while no differences were seen between the 
free NTF and control conditions.  
 
2.3. NTFs enhance axon outgrowth of motor and sensory neurons in vivo 
All the rats showed evidence of axonal regeneration after section of the sciatic 
nerve and tube repair, as judged by the retrograde labeling of motor and sensory 
regenerated neurons with FG (Fig. 6). No differences were found between groups 
treated with collagen alone and with MP-PBS (Fig. 7A, B) indicating again lack of 
interaction of PLGA MPs with axon outgroth.  
GDNF and BDNF applied as free factor in the nerve conduit were the only NTFs 
that enhanced motor axon regeneration in comparison with the control group, whereas 
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NT-3, FGF and NGF did not show differences (Fig. 7A). Similarly, free GDNF, BDNF 
and also FGF yielded significant differences in comparison with animals treated with 
MP-PBS. On the other hand, all the groups with NTFs encapsulated in MPs had higher 
number of regenerated motor neurons than the control group. Particularly, groups 
treated with MP-GDNF and MP-BDNF showed the highest increase in the number of 
regenerated motor axons. Concerning sensory neurons regeneration, only free NGF 
showed differences with the two control groups without NTF (Fig. 7B). In contrast, MP-
NGF, MP-GDNF and MP-BDNF enhanced sensory axon growth with respect to control 
and MP-PBS groups. 
With regard to the performance of MPs, a comparison of free NTF (dotted line, 
taken as 100%) with the same factor encapsulated in MPs is shown in Fig. 7C, D. For 
motor neurons, all the MP groups had higher numbers of neurons with regenerated 
axons in comparison with free NTF with the exception of FGF (Fig. 7C). For sensory 
neurons, all the MP groups had increased axon regeneration in comparison with free 
NTF, except for NGF and BDNF (Fig. 7D). These results indicate that the slow release 
of NTFs from MPs promoted nerve regeneration in vivo.  
Finally, histologic quantification of MF inside the regenerating tube was 
performed. The biocompatibility of the PLGA MPs used in this study was confirmed, as 
MPs were in close proximity with regenerated myelinated and unmyelinated axons (Fig. 
8 D, F). The regenerated nerve inside the tube had a thin external layer of fibrous 
tissue and a central region with axons forming the typical morphology of a regenerated 
nerve inside a tube (Gómez et al., 1996; Lago et al.,  2006) in all the groups (Fig. 8 A-
C). With regard to the number of MFs, control and MP-PBS groups showed similar 
values. On the other hand, only NGF and MP-NGF treated groups showed higher 
number of MFs than controls, whereas the other treated groups had similar values with 
no differences compared to the control groups (Fig. 8G).  
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3. Discussion 
The results of this study demonstrate that different NTFs encapsulated in PLGA 
MPs enhance motor and sensory axons regeneration both in vitro and in vivo in 
comparison with the same NTFs administered as free molecules without encapsulation. 
The encapsulation in controlled release systems has the advantage to allow a slow and 
sustained release of desired NTFs focally at selected areas of the nervous system as a 
therapeutical approach for neurodegenerative diseases and neural injuries (Benoit et 
al., 2000; Catrina et al., 2013). Due to their small size, MPs can be easily implanted in 
well localized areas without affecting the surrounding tissues (Fig. 3 & 8), thus avoiding 
also secondary effects. The controllable delivery of molecules from the MPs is 
advantageous as compared to a burst supply by direct injection and allows to 
overcome the limited therapeutic protein stability. Advantages of MPs (and conduits) as 
carriers for local, prolonged delivery of NTFs include that they are biocompatible and 
biodegradable, minimizing the foreign-body reaction, they avoid the implantation of 
catheters and external devices needed with injection ports and osmotic pumps, or the 
grafting of engineered cells with immunogenicity issues. 
First, a characterization of the PLGA MPs was made before their in vitro and in 
vivo use. ELISA results demonstrate that 10 days after MP fabrication, 30% of the 
encapsulated NTF has been already released, and that slow release is maintained for 
more than a month. This releasing profile seems adequate for enhancing nerve 
regeneration, since the expression of different NTF receptors remains upregulated 
during the firsts months after injury (Boyd and Gordon, 2003a). Despite previous 
studies have used PLGA MPs to deliver NTFs, mechanical and chemical stresses 
during MP manufacturing may affect the structure and the stability of the encapsulated 
protein (Yeo et al., 2004; Pfister et al., 2007). To address this issue, we first used 
organotypic cultures of DRG (Fig. 4) and SC (Fig. 5) to assess the bioactivity of NTFs 
released from the prepared MPs. The obtained results showed that the NTFs tested, 
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NGF and BDNF, are released in effective concentration beyond one week, and after 
this period still keep bioactivity to promote neurite outgrowth in comparison with the 
application of free NTFs. The neurite growth observed in cultures without 
preconditioning (i.e. immediate use) was similarly enhanced by free NTFs and by NTFs 
loaded in MPs added within the collagen matrix, which can be explained by the initial 
burst release of enough amount of the NTFs (Fig. 2). However, after 1 week of 
preconditioning the medium, only NTFs encapsulated in MPs produced an increase in 
neurite outgrowth in comparison with control cultures, indicating that MPs were still 
releasing NTFs at a concentration high enough to stimulate the growing response. 
Thus, rather than an increased effect of encapsulated NTFs over free NTFs, it seems 
that the elution of the free NTFs outside the matrix or the loss of their activity is 
responsible of the low effect in the conditioned setting, while the NTFs continuously 
released from the MPs were still able to enhance neurite outgrowth to similar levels 
than in the non-conditioned matrix.  
Second, after testing that the manufactured MPs did not interact with growing 
neurites and improved regeneration in vitro, the same preparations were applied in 
vivo. A silicone tube filled with a collagen gel containing either free or MPs 
encapsulated NTFs was implanted to repair a nerve gap. The NTFs applied were 
expected to act during the period of axonal regeneration across the tube, i.e. 2-3 weeks 
(Williams et al., 1983; Mcdonald et al., 2003). As the MP encapsulation increased the 
therapeutic window of NTFs delivery in vitro, its effects were presumed to be also 
higher in vivo than those of free NTFs. Thus, both retrotracer and histological analyses 
were conducted to test whether application of encapsulated NTF improved nerve 
regeneration in vivo.  
The number of regenerated neurons (Fig. 7A-B) and MFs (Fig. 8G) in both 
control groups was similar, indicating that the presence of PLGA MPs did not interfere 
in the regeneration process. On the other hand, while retrotracer analysis 
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demonstrates an enhancement of regeneration in all the groups with NTFs, this 
improvement is not seen in the histological analysis where only groups treated with 
NGF showed differences compared to control. Moreover, we found less regenerating 
neurons in the retrotracer study than MFs in the histology. Although this results could 
seem contradictory, it has been reported that neurons initially generate several axonal 
sprouts after axotomy (Mackinnon et al., 1991), and even at long term each neuron 
may maintain more than a single regenerated axonal branch (Gómez et al., 1996; Jenq 
& Coggeshall, 1985). Furthermore, more regenerated axons (sprouts) do not 
necessarily indicate more neurons regenerating (Piquilloud et al., 2007) and may be 
also considered deleterious in terms of functional recovery (Guntinas-Lichius et al., 
2005). Hence, the increase of MF in the NGF groups would be in accordance with 
other studies that describe an important role of NGF on axonal sprouting (Diamond et 
al., 1987; Gloster et al., 1992; Ruiz et al., 2004). Thus, histological quantification of 
MFs may result in an overestimation of the number of regenerated neurons (Navarro 
2015) and only the retrotracer study provides reliable information on the number of 
regenerating neurons. For these reasons, in our study the positive effects of the NTFs 
loaded MPs were indicated by the effective growth of axons that were able to capture 
the retrotracer placed distal to the nerve conduit. 
The results found in this work indicate that an increased number of motor and 
sensory neurons regenerate distally to the nerve conduit in the groups with MP-
encapsulated NTFs. This can be explained by an acceleration of axonal regeneration, 
as well as by an indirect effect inducing endogenous Schwann cells to a 
proregenerative state (Gordon et al., 2003). After nerve lesion reactive Schwann cells 
highly induce the expression of several NTFs, including NGF, BDNF, GDNF, and their 
receptors (Boyd and Gordon, 2003a; Allodi et al., 2012). The increased neurotrophic 
secretion peaks at about 1 week postaxotomy and declines with time. Our results give 
further support to the view that additional exogenous supply of NTFs may enhance the 
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regenerative response of peripheral neurons. Nevertheless, the concentration and time 
window of the NTFs applied at the site of nerve injury, such as within a nerve conduit, 
need to be carefully investigated. Indeed, a small supply of a NTF at the site of injury 
does not always have beneficial effects, and on the opposite an excessive 
concentration may even hinder axonal growth. Thus, exogenous application of NGF to 
axotomized sensory neurons may interfere with the regenerative response and delay 
axonal regrowth (Gold et al., 1997; Mohiuddin et al 1999). An increased supply of 
GDNF at the focal site has been shown to stimulate axonal sprouting, thus multiplying 
the number of regenerating fibers within a nerve conduit, but did not result in positive 
outcomes in terms of distal regeneration and return of motor function (Piquilloud et al., 
2007). A further problem was reported after the injection in the injured nerve of viral 
vectors transducing the over-expression of NTFs. The high amount of GDNF secreted 
created a “candy-store” effect (Tannemaat et al., 2008), in which regenerating axons 
stay in areas with high GDNF concentration and fail to grow distally towards the target 
organs. Therefore, our results sustain that prolonged, controlled release of NTFs is 
beneficial to improve nerve regeneration.  
Third, after fluorogold retrolabeling and quantification of regenerated neurons in 
DRG and SC (Fig. 7), we were able to distinguish if different NTFs exerted a selective 
effect on the axonal regeneration of motor or sensory neurons in vivo, an information 
that is not provided by standard microscopy methods. The in vivo results corroborated 
some results previously reported using the organotypic cultures in vitro. Thus, in 
cultures with NTFs added directly to the collagen matrix, NGF had a positive effect only 
on sensory neurons, BDNF mainly enhanced motoneurons growth, GDNF promoted 
neurite outgrowth in both types of neurons, whereas NT-3 did not have a noticeable 
effect (Allodi et al., 2011), similarly to our results in vivo with free NTFs. Nevertheless, 
we found that when applied encapsulated in MPs, the same NTFs had stronger effects 
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on axonal regeneration of both populations of peripheral neurons, although the 
differential effects were maintained. 
Previous studies demonstrated that an additional supply of GDNF and of BDNF 
exerts beneficial effects on motoneuron survival and regeneration (Boyd and Gordon, 
2003b; Pajenda et al., 2014), but no positive effects were found for sensory neurons 
(Tannemaat et al., 2008). In agreement with those reports, we observed improved 
motor but not sensory neuron regeneration when BDNF and GDNF were embedded as 
free factors in the collagen filling the silicone tube. However, when they were 
encapsulated in MPs, regeneration was enhanced in both motor and sensory neurons. 
Although sensory neurons and Schwann cells express both BDNF and GDNF 
receptors (Boyd and Gordon, 2003a), it is likely that a single administration immediately 
after nerve injury is not enough to exert a significant effect on sensory regeneration. 
FGF-2 is expressed in three isoforms that are upregulated after nerve injury 
(Klimaschewski et al., 2013). FGF-2 18 KDa isoform mainly enhances motor functional 
recovery with some effects on sensory functional recovery (Allodi et al., 2014; Haastert 
et al., 2006; Meyer et al., 2015). In accordance with these studies, we found an 
enhancement only of motor axon regeneration compared to both controls in the MP 
group. 
On the other hand, as motoneurons do not express TrkA receptor and after 
sciatic nerve axotomy TrkC receptor levels remain relatively unchanged (Boyd and 
Gordon, 2003a), significant effects on motoneurons regeneration with the application of 
NGF and NT-3 were not expected. However, when encapsulated in MPs both NGF and 
NT-3 produced significant increase in the number of motoneurons that regenerated 
their axons distal to the conduit. A previous study described improvement of motor 
regeneration with NGF administration in a fibrin depot (Jubran et al., 2003). It may be 
hypothesized that the prolonged supply by the MPs might indirectly enhance axonal 
regeneration by stimulating Schwann cell proliferation and reactivity. Furthermore, a 
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possible inhibition of NGF or NT-3 via p75 receptor activation (Boyd and Gordon, 2002) 
could also be compensated by the upregulation of other NTFs such as BDNF secreted 
by stimulated Schwann cells or fibroblasts (Acheson et al., 1991; Klein et al., 1991). 
In conclusion, the results of this study indicate that the use of PLGA MPs as a 
prolonged delivery system within a nerve conduit is a good approach to enhance nerve 
regeneration in comparison with a single application of NTFs that have a limited effect 
due to degradation, leakage outside the conduit or dilution resulting in sub-optimal 
concentration. Despite some NTFs are able to enhance axonal regeneration when 
directly applied to the injured nerve, our in vitro and in vivo results support that the 
therapeutic effect in terms of increasing axon growth is significantly increased by a 
sustained release from PLGA MPs. The lengthening of trophic support will be of further 
relevance for the repair of long gaps with nerve conduits, a situation in which the 
endogenous support is insufficient to sustain axonal regeneration, as well as for 
delayed repair of nerve injuries (Wood et al., 2013) that need a reactivation of the pro-
regenerative environment along the distal nerve. Further research to refine the MPs 
supply of NTFs should address on tuning the time-concentration rate of delivery, as 
well as the potential contribution of several factors simultaneously or sequentially. 
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4. Experimental Procedure 
4.1. Microsphere fabrication and characterization 
The chosen material was Poly-lactic Co-Glycolic acid (PLGA, Sigma-Aldrich Co. 
LLC, cat# 719870), a synthetic biocompatible and biodegradable co-polymer widely 
used for controlled release applications (Makadia et al., 2011). Low molecular weight 
PLGA (Mw 24,000-38,000) was used because of its encapsulation efficiency (Blanco 
and Alonso, 1998) and a water-in-oil-in-water (WoW) protocol was followed, as already 
described (Ghaderi et al., 1996), with modifications to adapt to the application. Briefly, 
30-35 mg of PLGA (50:50) were dissolved in 1 ml DCM. The first emulsion was created 
with 200 µl aqueous solution of the desired trophic factor (NGF, BDNF, GDNF, FGF-2 
18 kDa, or NT-3, Peprotech, USA) with an immersion homogenizer. This water-in-oil 
emulsion was then poured in 7 ml PVA 5% aqueous solution to create the second 
emulsion. After 45 min in the magnetic stirrer the double emulsion was poured in 40 ml 
PVA 0.1% aqueous solution to allow for solidification and solvent evaporation over 16h 
in the magnetic stirrer at RT. The MPs were washed with distilled water twice by 
centrifugation at 4650 RCF at 4°C, finally resuspended in an aqueous solution with 
penicillin/streptomicyn, to control possible downstream bacterial contamination and 
sent forth for in vitro/in vivo experiments. 
MP surface and size distribution assessment was performed by SEM 
(EVO™MA10 Scanning Electron Microscope, Zeiss, Germany). Briefly, 1-3 µl of 
particles dispersion were spotted on silicone stubs, metallized with a sputter coater 
(Quorum Q150R ES, Quorum technologies, UK) and imaged with an acceleration 
voltage of 10 kV. Size distribution characterization was performed by means of an 
inverted microscope (Eclipse Ti; Nikon Instruments, Japan) equipped with a cooled 
CCD camera (DS-Fi1C; Nikon Instruments, Japan). MPs were imaged immediately 
after synthesis in 5 μl distilled water spotted on a clean glass coverslip, and snapshots 
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of random fields were taken in visible light. Particle size was evaluated via image 
analysis with the Fiji software (Schindelin et al., 2013). Assessment of fluorescent 
proteins encapsulation and tracking was performed with same apparatus equipped with 
suitable fluorescent filters. 
NGF was chosen to further characterize the performance of the microspheres 
system. NGF encapsulation efficiency of the fabrication protocol was calculated as the 
fraction between experimental load versus theoretical load. For efficiency testing, 4 µg 
of NGF were encapsulated in 30 mg PLGA MPs, following the above described 
protocol. The MPs were washed and dissolved by incubation overnight in 2 ml 
dissolution buffer (5% SDS, 0.1N NaOH) at RT. Following microsphere dissolution, the 
released NGF was quantified with an ELISA test kit (Human beta-NGF ELISA kit, 
Sigma-Aldrich, USA), following the manufacturer’s protocol. 
For NGF release assessment, a tube containing 1 ml of phosphate buffered 
saline (PBS) was loaded with 62.5 µg of MPs coming from batches of 30 mg total 
mass, equivalent to an estimated 50 ng encapsulated NGF (based on previously 
calculated load efficiency). The tube was incubated at 37°C and at specific time points 
(0, 1, 2, 3, 5, 6, 7, 8, 15, 20, 25, 33 days), the mixture was centrifuged at 4650 RCF at 
4°C, the supernatant was collected and fresh PBS was then added to replace the 
withdrawn supernatant; the MPs were resuspended again and returned to 37°C. 
Supernatants were frozen for subsequent quantification. Assessment of quantity of the 
released NGF in each supernatant at different time points was also performed by an 
ELISA kit (Human beta-NGF ELISA kit SIGMA-Aldrich, USA), following the 
manufacturer’s protocol. Release experiments were all performed in duplicate. 
 
4.2. In vitro study on organotypic cultures 
The in vitro procedures were approved by the ethical committee of the 
Universitat Autonoma de Barcelona in accordance with the European Communities 
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Council Directive 2010/63/EU. Organotypic cultures were prepared as previously 
described (Allodi et al., 2011). A volume of 392 µl of rat tail collagen type I solution 
(#354236, Corning) at a concentration of 3.83 mg/ml was mixed with 50 µl of 10× basal 
Eagle’s medium (Gibco) and 2 µl of 7.5% sodium bicarbonate solution. Moreover, 56 µl 
of PBS with MPs containing FITC-BSA for biocompatibility assessment or 56 µl of PBS 
with free or MP encapsulated NGF or BDNF for bioactivity experiments were added to 
the collagen solution. The same volume of MPs with PBS vehicle was used for the 
control group (Col). The final concentration of the NTF was 10 ng/ml of within a 3.0 
mg/ml collagen gel. 
Single drops of 30 µl were deposited on poly-d-lysine (PL, 1 g/ml, Sigma) 
coated coverslips, which were placed in Petri dishes or 24-well multidishes (Iwaki, 
Asahi Technoglass, Chiba, Japan) and kept in the incubator at 37ºC and 5% CO2 for 
two hours to induce collagen gel formation. Three different sets of collagen-based 
matrices (containing MPs loaded with PBS, NTFs or free NTFs) were prepared and 
used immediately or maintained for 1 week (conditioning) in the incubator to test if MPs 
released the factors over time and if the NTF was accumulated or eluted with time in 
each condition. 
P7 rats were euthanised by cervical dislocation following AVMA Guidelines on 
Euthanasia (Leary et al., 2013), and spinal cord (SC, n=6-8/group) lumbar segments 
and lumbar DRG (n=14-24/group) were harvested, placed in cold Gey’s balanced salt 
solution (Sigma) enriched with 6 mg/ml glucose and cleaned from blood and meningeal 
debris. SCs were cut with a McIlwain Tissue Chopper in 350 µm thick slices. SC slices 
and DRG explants were then placed on the gelled collagen droplets, prepared as 
indicated above, and covered by a second drop of 30 µl collagen matrix. The 
embedded samples were placed again in the incubator for 45 min before adding 
Neurobasal medium (NB, Invitrogen), supplemented with B27 (Invitrogen), glutamine 
and penicillin/streptomycin (Sigma). The medium volume delivered into Petri dishes 
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and wells was 1.5 ml for SC slices and 0.5 ml for DRG. After one day in culture, the 
medium of SC cultures was removed and changed by a penicillin/streptomycin free 
medium. DRG explants were cultured for 2 days, and SC slices for 4 days. 
 SC and DRG cultures were fixed with 4% paraformaldehyde in PBS for 30 min. 
Afterwards, SC and DRG samples were incubated for 48 h with primary antibody 
mouse RT97 (1:200, Developmental Studies Hybridoma Bank) at 4ºC. After three 
hours washing, the sections were incubated with secondary antibodies AF594 
conjugated donkey anti-mouse (1:200, Jackson IR) overnight at 4ºC. After two washes 
samples were mounted on slides with Mowiol containing DAPI (1:10000, Sigma) 
nuclear counterstain. Cultures were visualized with an Olympus BX51 fluorescence 
microscope, images of different areas were taken with Cell A software (Olympus) and 
merged using Adobe Photoshop CS3 (Adobe System). Confocal images were obtained 
using a ZEISS LSM 700 microscope and the ZEN ZEISS software. Whole culture 
images were analyzed with the Neurite-J plug-in (Torres-Espín et al., 2014) for ImageJ 
software (NIH, available at http://rsb.info.nih.gov/ij/) and the number of neurites grown 
at different distances from the explant was compared between sets of cultures.  
 
4.3. In vivo study of peripheral nerve regeneration 
Female Sprague-Dawley rats (250–300 g) were used for the in vivo studies. 
They were kept on standard laboratory conditions with a light-dark cycle of 12:12 h and 
ad libitum access to food and tap water. All efforts were made to minimize pain and 
animal discomfort during surgery and treatments. 
Animals were anaesthetized with pentobarbital sodium (40 mg/kg i.p.)., the 
sciatic nerve was exposed at the midthigh and sectioned 90 mm from the tip of the third 
toe, and a 6 mm nerve portion distal to the section was resected. A silicone tube was 
then sutured with 10-0 monofilament sutures to each nerve stump leaving a 6 mm gap 
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between both nerve ends. Animals were kept for 20 days post-operation (dpo) to allow 
axonal regeneration before testing. 
NGF, NT-3, GDNF and BDNF free or encapsulated in MPs were added to a 
collagen solution to reach a final concentration of 2 µg/ml; FGF free and encapsulated 
was used at 10 µg/ml. Each preparation of NTF was mixed with 50 µl of 10× basal 
Eagle’s medium (Gibco), 2 µl of 7.5% sodium bicarbonate and 187 µl of PBS, and then 
kindly mixed with 261 µl of collagen type I solution at 3.83 mg/ml to a reach a final 
collagen concentration of 2 mg/ml. Silicone tubes 8 mm long with an external diameter 
of 3 mm and an internal diameter of 2 mm were filled with one of the collagen mixtures 
containing free or encapsulated NTFs. In order to promote fibril alignment, the collagen 
was left to gel vertically for 12 hours before surgery (Verdú et al., 2002). Therefore, 
there were 10 experimental groups (n=5-6 per group), one for each NTF free and 
encapsulated in MPs. In addition, two control groups were implanted with tubes 
containing collagen alone or collagen with MPs containing only PBS. All in vivo 
procedures were approved by the ethical committee of the Universitat Autonoma de 
Barcelona in accordance with the European Communities Council Directive 
2010/63/EU. 
 
4.4. Retrograde labeling and neuronal counting 
To quantify regenerated motor and sensory neurons, rats were anaesthetized at 
20 days after lesion with pentobarbital sodium, the sciatic nerve was exposed and 
transected 8 mm distal to the distal end of the silicone tube. The tip of the severed 
nerve was soaked into 5 µl of Fluorogold (FG; 5%; Fluorochrome Inc.) for 1 hr in a 
vaseline well. After retrieval of the well, the area was rinsed with saline to clean 
remnants of the tracer, and the wound sutured in planes. Animals were allowed to 
survive for 7 days to allow accumulation of the tracer in the soma of the spinal 
motoneurons and the DRG sensory neurons. Then, rats were deeply anesthetized with 
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pentobarbital sodium overdose (200 mg/kg i.p.) following AVMA Guidelines on 
Euthanasia (Leary et al., 2013) and transcardially perfused with 4% paraformaldehyde 
in PBS. The lumbar segment (L3-L6) of the SC and L4 and L5 DRG were removed, 
postfixed in the same fixative solution for 1h and transferred to 30% sucrose in PBS. 
The SC and DRG were cut longitudinally in 40 and 20 µm thick sections, respectively, 
in a cryostat and mounted on slides. Sections were observed with an Olympus BX51 
fluorescence microscope under UV light and the number of labeled neurons were 
counted in every third section following the fractionator principle (Gundersen et al., 
1986). 
 
4.5. Nerve histology 
After perfusion, the regenerated nerves inside the tubes were also harvested 
and fixed in glutaraldehyde-paraformaldehyde (3%/3%) in cacodylate-buffer solution 
(0.1 M, pH 7.4) overnight at 4ºC. Then, nerves were postfixed with osmium tetroxide 
(2%, 2 h) and dehydrated through ethanol series prior to embedding samples in epon 
resin. Semithin sections (0.5 µm thick) taken 3mm distal from the proximal stump were 
stained with toluidine blue and examined by light microscopy. Images of the whole 
sciatic nerve were acquired at 10× with an Olympus DP73 camera attached to a 
computer. Sets of images for analysis obtained at 100× magnification were chosen by 
systematic random sampling of squares representing at least 30% of the nerve cross-
sectional area and measurements of cross-sectional area of the whole nerve and 
counts of the number of myelinated nerve fibers (MF) were conducted. 
 
4.6. Data analysis and statistics 
Data are presented as mean ± SEM. Results were statistically analyzed by 
using GraphPad Prism (GraphPad Software, USA). One- or two-way ANOVA followed 
by Bonferroni’s multiple comparison test was used in the in vitro studies for comparison 
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between groups. Student’s t-test or one-way ANOVA followed by post hoc Fisher's 
exact test were applied in the in vivo studies. Statistical significance was considered 
when P value was <0.05. 
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7. Figure legends: 
Figure 1: A, B: Steps in image treatment for automated microspheres counting. A: 
starting, as-is, captured image of microspheres suspension in visible light; B: same 
image after normalization, thresholding, binarization and automatic recognition for 
counting. C: sample SEM micrograph of PLGA MPs showing regular surface 
roughness. D: statistical data distribution for MPs counted with the automated 
procedure from A, B.  
 
Figure 2: Cumulative release of NGF from PLGA MPs, measured by ELISA and 
expressed as percentage of an estimated starting total concentration of 50 ng/ml of 
neurotrophin. Data expressed as mean ± SEM. 
 
Figure 3: Neurite outgrowth stained with RT97 (red) from DRG (A) and SC (B) 
organotypic cultures in a collagen matrix filled with fluorescent MPs (green). Scale bar: 
100 μm.  
 
Figure 4: A-C: Neurites stained with RT97 from DRG neurons cultured within non-
conditioned collagen alone (A), with added free NGF (B), and MP-NGF (C). D-F: 
Neurite outgrowth from DRG neurons cultured within 1 week-conditioned collagen 
matrix alone (D), with added free NGF (E), and MP-NGF (F). G, I: Plot of the number of 
neurites grown at increasing distance from the DRG body in a collagen matrix non-
conditioned (G) and after 1 week conditioning with free NGF or MP-NGF (I). H, J: 
Measurement of the longest neurite in non-conditioned (H) and after 1 week 
conditioning with free NGF or MP-NGF (J). *p<0.05 vs Col; $p<0.05 vs MP-NGF; 
#p<0.05 vs free NGF, & p<0.05 vs free NGF and MPNGF. Data expressed as mean ± 
SEM. Scale bar: 250 μm.  
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Figure 5: A-C: Neurites stained with RT97 from SC neurons cultured within non-
conditioned collagen alone (A), with added free BDNF (B), and MP-BDNF (C). D-F: 
Neurite outgrowth from SC neurons cultured within 1 week-conditioned collagen matrix 
alone (D), with added free BDNF (E), and MP-BDNF. G, I: Plot of the number of 
neurites grown at increasing distance from the SC body in a collagen matrix non-
conditioned (G) and after 1 week conditioning with free BDNF or MP-BDNF (I). H, J: 
Measurement of the longest neurite in non-conditioned (H) and after 1 week 
conditioning with free BDNF or MP-BDNF (J). *p<0.05 vs Col; $p<0.05 vs MP-BDNF, 
#p<0.05 vs free BDNF, & p<0.05 vs free BDNF and MP-BDNF. Data expressed as 
mean ± SEM. Scale bar: 250 μm. 
 
Figure 6: Representative micrographs of neurons retrolabeled with FG in the lumbar 
SC of rats after sciatic nerve section and repair with a nerve conduit filled with collagen 
plus MP-BDNF (A, left) and with collagen alone (A, right). Representative micrographs 
of neurons retrolabeled with FG in the lumbar DRG of rats after sciatic nerve section 
and repair with a nerve conduit filled with collagen alone (B) and with collagen plus MP-
NGF (C). Scale bar: 500 μm.  
 
Figure 7: Histograms of the number of motor neurons in the SC (A) and of sensory 
neurons in the DRG (B) retrolabeled with FG after sciatic nerve section and conduit 
repair counted in the different groups compared, with and without NFs in free and in 
MP preparations. Percentage of retrolabeled motor (C) and sensory (D) neurons 
counted in rats with NTF loaded MPs with respect to rats with the same NTF applied as 
free factor in the collagen gel. Data expressed as mean ± SEM. *p<0.05 vs Col; 
#p<0.05 vs MP-PBS. 
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Fig. 8. A-F: Representative microphotographs of semithin transverse sections of the 
regenerated nerves in groups MP-PBS (A, D), NGF (B, E) and MP-NGF (C, F). G: 
Histogram of myelinated fibers number in the different groups compared. Data 
expressed as mean ± SEM. *p<0.05 vs Col; #p<0.05 vs MP-PBS. Scale bar 100 μm in 
A-C and 10 μm in D-F. 
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